BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29766298)

  • 1. K27/G34 versus K28/G35 in histone H3-mutant gliomas: A note of caution.
    Leske H; Rushing E; Budka H; Niehusmann P; Pahnke J; Panagopoulos I
    Acta Neuropathol; 2018 Jul; 136(1):175-176. PubMed ID: 29766298
    [No Abstract]   [Full Text] [Related]  

  • 2. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review.
    Lasocki A; Abdalla G; Chow G; Thust SC
    Cancer Imaging; 2022 Nov; 22(1):63. PubMed ID: 36397143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
    Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
    Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
    Nazem A; Lavezo J; Abdullaev Z; Aldape K; Quezado M; Cimino PJ; Pratt DW; Jenkins RB; Ida CM
    J Neuropathol Exp Neurol; 2023 Dec; 83(1):58-60. PubMed ID: 37878797
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.
    Vettermann FJ; Felsberg J; Reifenberger G; Hasselblatt M; Forbrig R; Berding G; la Fougère C; Galldiks N; Schittenhelm J; Weis J; Albert NL; Schüller U
    Clin Nucl Med; 2018 Dec; 43(12):895-898. PubMed ID: 30358620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity.
    Korshunov A; Capper D; Reuss D; Schrimpf D; Ryzhova M; Hovestadt V; Sturm D; Meyer J; Jones C; Zheludkova O; Kumirova E; Golanov A; Kool M; Schüller U; Mittelbronn M; Hasselblatt M; Schittenhelm J; Reifenberger G; Herold-Mende C; Lichter P; von Deimling A; Pfister SM; Jones DT
    Acta Neuropathol; 2016 Jan; 131(1):137-46. PubMed ID: 26482474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling.
    Chen KY; Bush K; Klein RH; Cervantes V; Lewis N; Naqvi A; Carcaboso AM; Lechpammer M; Knoepfler PS
    Commun Biol; 2020 Jul; 3(1):363. PubMed ID: 32647372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
    Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
    Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
    Kasper LH; Baker SJ
    Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
    Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
    Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
    Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
    Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literature.
    Roach JT; Riviere-Cazaux C; Wells BA; Boop FA; Daniels DJ
    Childs Nerv Syst; 2024 Jul; 40(7):2009-2017. PubMed ID: 38613587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
    Wood MD; Neff T; Nickerson JP; Sayama C; Raslan AM; Ambady P; Corless CL; Nazemi KJ
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):460-463. PubMed ID: 33296093
    [No Abstract]   [Full Text] [Related]  

  • 18. TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas.
    Chan AK; Mao Y; Ng HK
    N Engl J Med; 2016 Dec; 375(22):2206-2208. PubMed ID: 27959765
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
    Sloan EA; Cooney T; Oberheim Bush NA; Buerki R; Taylor J; Clarke JL; Torkildson J; Kline C; Reddy A; Mueller S; Banerjee A; Butowski N; Chang S; Mummaneni PV; Chou D; Tan L; Theodosopoulos P; McDermott M; Berger M; Raffel C; Gupta N; Sun PP; Li Y; Shah V; Cha S; Braunstein S; Raleigh DR; Samuel D; Scharnhorst D; Fata C; Guo H; Moes G; Kim JYH; Koschmann C; Van Ziffle J; Onodera C; Devine P; Grenert JP; Lee JC; Pekmezci M; Phillips JJ; Tihan T; Bollen AW; Perry A; Solomon DA
    Acta Neuropathol; 2019 Nov; 138(5):877-881. PubMed ID: 31515627
    [No Abstract]   [Full Text] [Related]  

  • 20. Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Lucas CG; Mueller S; Reddy A; Taylor JW; Oberheim Bush NA; Clarke JL; Chang SM; Gupta N; Berger MS; Perry A; Phillips JJ; Solomon DA
    Neuro Oncol; 2021 Nov; 23(11):1974-1976. PubMed ID: 34519829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.